All In Biotech

Drug Trial Radar · NCT00188604

The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer

A Randomized Phase II Placebo-controlled Double Blind Study of Using Selenium in the Treatment of Secondary Lymphedema in Breast Cancer Patients

Last checked: Nov 20, 2026Latest source record: Aug 13, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Planned (sponsor's estimate)

Start

Jan 2004

Primary completion

Jan 2009

Study completion Jan 2009

Sponsor

Lead sponsor
University Health Network, TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Princess Margaret Hospital, Canada
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study to assess the effectiveness of selenium compared to placebo in reducing the lymphedema in-patients with breast cancer. Secondary objectives are to assess the impact of selenium on patient's quality of life and to assess the incidence of adverse effects of selenium therapy.

Conditions

  • Breast Neoplasms
  • Lymphedema

Interventions

  • sodium seleniteDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the effectiveness of orally administered selenium compared to placebo in reducing arm lymphedema in patients treated with surgery (axiallary nodal dissection) and radiotherapy for breast cancer.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.